Ramesh succeeds David Livingston, MD, who has been the only person to hold the position of Deputy Director since DF/HCC won NCI designation as a comprehensive cancer center consortium in 1999. We are fortunate that David will remain an active member of the DF/HCC Breast Cancer and Cancer Genetics research programs after stepping down as Deputy Director.
Ramesh is an inaugural member of DF/HCC who currently serves as leader of the Gastrointestinal Malignancies program. At DFCI he is a medical oncologist and laboratory investigator in the Gastrointestinal Cancer Center and is Professor of Medicine at HMS. He is also co-director of the Cancer Program and member of the Executive Committee of the Harvard Stem Cell Institute. He is a member of the American Society for Clinical Investigation and the Association of American Physicians.
Ramesh has held positions at Harvard institutions since the time of his post-graduate training. After receiving his MD and PhD from the University of Michigan, he completed a residency in internal medicine at BWH and a fellowship in medical oncology at DFCI. As a postdoctoral fellow at BCH working with Stuart Orkin, he investigated transcriptional regulation and hematopoiesis. Ramesh’s laboratory now studies mechanisms of development, cell differentiation, and tumorigenesis in the gastrointestinal tract, with particular focus on transcription factors and chromatin states. He is a project co-leader on the DF/HCC GI Malignancies SPORE and collaborates with others across the DF/HCC institutions.
Succeeding David Livingston will be no small feat. For more than 20 years David has been the guiding force behind the success of DF/HCC. At the beginning David co-chaired the 40-person grant planning committee that convened in the summer of 1997 to establish the founding vision of our consortium cancer center, and through his non-stop efforts since then our cancer center has grown to more than 1,100 members. He has worked tirelessly with Tyler Jacks at the Koch Institute for Integrative Cancer Research at MIT to secure private funding in excess of $34M to establish and sustain the Bridge Project, a unique inter-cancer center program between DF/HCC and MIT which has funded 46 collaborative research projects since 2012. His devotion to DF/HCC has been a true labor of love that has been critical to our lasting success as a consortium. We all owe David a debt of gratitude for his service on our behalf.
Ramesh will work with David on the transition in the coming months, until he fully assumes the Deputy Director role in March 2019. Please join me in congratulating Ramesh in his new role.
Laurie H. Glimcher, M.D.
Director, Dana-Farber/Harvard Cancer Center